MedTrace Logo

Carboplatin and Irinotecan in Treating Children With Refractory Solid Tumors

NCT00024284 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL

Last updated 2013-04-05

No results posted yet for this study

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.

PURPOSE: Phase I trial to study the effectiveness of combining carboplatin and irinotecan in treating children who have refractory solid tumors.

Conditions

  • Unspecified Childhood Solid Tumor, Protocol Specific

Interventions

DRUG

carboplatin

DRUG

irinotecan hydrochloride

Sponsors & Collaborators

Principal Investigators

  • Ashwin Gollerkeri, MD · Bristol-Myers Squibb

Study Design

Purpose
TREATMENT

Eligibility

Min Age
1 Year
Max Age
21 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2001-06-30
Primary Completion
2003-12-31
Completion
2003-12-31

Countries

  • United States
  • Canada

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00024284 on ClinicalTrials.gov